{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:11:08Z","timestamp":1793725868410,"version":"4.6.1"},"reference-count":14,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2021,7]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Minority RBC donors are important to support the transfusion needs of patients with sickle cell disease. Testing of donors for sickle cell trait (SCT) is performed to avoid transfusion of hemoglobin S+ (HbS+) RBCs to specific patient groups and to investigate leukoreduction failures. A screening assay based on hemoglobin solubility is commonly used. The purpose of this study was to validate a DNA approach for HbS screening.<\/jats:p><\/jats:sec>Methods<\/jats:title>Hemoglobin solubility screening (Pacific Hemostasis or SICKLEDEX) and PreciseType human erythrocyte antigen (HEA)\u2010HbS (Immucor) targeting c.20A>T in the \u03b2\u2010globin gene were performed according to manufacturer's directions. Resolution of differences in results included gene sequencing and high\u2010performance liquid chromatography (HPLC).<\/jats:p><\/jats:sec>Results<\/jats:title>Initial validation of HEA\u2010HbS performed by testing 60 known samples, 20 HbS\/A, A\/A, and S\/S, gave expected results. However, in the subsequent parallel testing phase, 4\/58 samples HbS+ by solubility assay tested negative by HEA\u2010HbS; the negative results were confirmed by \u03b2\u2010globin gene sequencing. Samples from donors self\u2010identifying as White testing HbS+ by solubility assay (n<\/jats:italic>\u00a0=\u00a060) were retested by HEA\u2010HbS and HPLC. The HEA\u2010HbS assay was concordant with HPLC which is recognized as the gold standard for hemoglobin variation.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>A DNA\u2010based approach is an alternative to screen donors for SCT, found in approximately 7% of Black and 1.7% of our random donors. HEA\u2010HbS correlated with HPLC results in all samples tested, supporting the use of HEA\u2010HbS as the test of record. The method allows higher throughput screening and testing at the donor center allows association of the screening result with the donor record to avoid repeat testing.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.16403","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T11:37:56Z","timestamp":1619782676000},"page":"2008-2013","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Screening of blood donors for sickle cell trait using a DNA<\/scp>\u2010based approach: Frequency in a multiethnic donor population"],"prefix":"10.1111","volume":"61","author":[{"given":"Lohith","family":"Gowda","sequence":"first","affiliation":[{"name":"Immunohematology and Genomics Laboratory, New York Blood Center Enterprise New York New York USA"},{"name":"Section of Hematology, Yale Cancer Center Yale University School of Medicine New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0243-266X","authenticated-orcid":false,"given":"Sunitha","family":"Vege","sequence":"additional","affiliation":[{"name":"Immunohematology and Genomics Laboratory, New York Blood Center Enterprise New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Kessler","sequence":"additional","affiliation":[{"name":"Immunohematology and Genomics Laboratory, New York Blood Center Enterprise New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2270-4821","authenticated-orcid":false,"given":"Beth","family":"Shaz","sequence":"additional","affiliation":[{"name":"Immunohematology and Genomics Laboratory, New York Blood Center Enterprise New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1929-4593","authenticated-orcid":false,"given":"Connie M.","family":"Westhoff","sequence":"additional","affiliation":[{"name":"Immunohematology and Genomics Laboratory, New York Blood Center Enterprise New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.10"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001143"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2009.12.022"},{"key":"e_1_2_6_5_1","volume-title":"Standards for blood banks and transfusion services","author":"AABB","year":"2020"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/524513"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490623"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation.V2015.1.433.3919686"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2004.03.002"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/19.5.533"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2044.2002.02517.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.25.5.458"},{"key":"e_1_2_6_13_1","unstructured":"JMenitove.Forty Fifth Meeting of the Advisory Committee on blood and tissue safety and availability (ACBTSA) recommendations. Health LtASo ed.https:\/\/www.hhs.gov\/sites\/default\/files\/ash\/bloodsafety\/advisorycommittee\/recommendations\/nov2014-recommendations.pdf 2014."},{"key":"e_1_2_6_14_1","unstructured":"AABBThe 112th Meeting of Blood Products Advisory Committee (BPAC) to Food And Drug Administration [monograph on the internet].http:\/\/www.aabb.org\/advocacy\/government\/bpac\/Pages\/bpacmeeting150513.aspx;2015."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12143"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16403","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.16403","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:44:17Z","timestamp":1693356257000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.16403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1111\/trf.16403"],"URL":"https:\/\/doi.org\/10.1111\/trf.16403","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,30]]},"assertion":[{"value":"2020-07-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}